A Single Shot Pre-fusion-Stabilized Bovine RSV F Vaccine is Safe and Effective in Newborn Calves with Maternally Derived Antibodies

Autor: David Gauthier, Peter D. Kwong, Karin Vargmar, Sara Bergström Lind, Sara Hägglund, Alexander Falk, Geraldine Taylor, Efrain Guzman, Baoshan Zhang, Sabine Riffault, Luc Jouneau, Daphné Laubreton, Jean-François Eléouët, Jean-Francois Valarcher, Aude Remot, Ganna Shevchenko, Vincent Pietralunga, Marga Garcia Duran, Catherine Dubuquoy, Olivier Boulesteix, María Jose Rodriguez, Abdelhak Boukaridi, Isabelle Schwartz-Cornil, Katarina Näslund
Přispěvatelé: Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Swedish University of Agricultural Sciences (SLU), The Pirbright Institute, Plateforme d'Infectiologie Expérimentale (PFIE), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Infectiologie et Santé Publique (UMR ISP), Université de Tours-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Génétique Animale et Biologie Intégrative (GABI), Université Paris-Saclay-AgroParisTech-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Uppsala University, National Institute of Allergy and Infectious Diseases [Bethesda] (NIAID-NIH), National Institutes of Health [Bethesda] (NIH), INGENASA, National Institute of Allergy and Infectious Diseases, NIAID National Institutes of Health, NIH Saint Louis University, SLU Uppsala Universitet, Funding: This project has received funding from the European Union’s Horizon 2020 Program for research, technological development, and demonstration under the Grant Agreement n633184 (Project’s name SAPHIR). Funding was also provided by the Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH) (MD, USA). This publication reflects the views only of the authors, and not the European Commission (EC) nor the NIH. The EC nor the NIH is not liable for any use that may be made of the information contained herein., Acknowledgments: We thank the experimental farm INRAE Le Pin (https://www6.rennes.inrae.fr/domaine-experimental-du-pin_eng/) for providing the calves and INRAE PFIE (https://www6.val-de-loire.inrae.fr/pfie_eng/) for housing the vaccine trial. We thank the histology facility of @Bridge of UMR GABI and the MIMA2 platform for access to the virtual slide scanner (Pannoramic SCAN, 3DHISTECH), Jouy-en-Josas, France. We also thank the Cells for Life Platform, partly funded by the Infrastructure Committee at SLU, (Uppsala, Sweden), for providing facilities and equipment. This work was supported by the Mass Spectrometry-based Proteomics Facility at Uppsala University., European Project: 633184,H2020,H2020-SFS-2014-2,SAPHIR(2015), Université de Tours (UT)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), AgroParisTech-Université Paris-Saclay-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Zdroj: Vaccines
Volume 8
Issue 2
Vaccines, Vol 8, Iss 231, p 231 (2020)
Vaccines, MDPI, 2020, 8 (2), 21 p. ⟨10.3390/vaccines8020231⟩
Vaccines, 2020, 8 (2), 21 p. ⟨10.3390/vaccines8020231⟩
ISSN: 2076-393X
DOI: 10.3390/vaccines8020231
Popis: International audience; Achieving safe and protective vaccination against respiratory syncytial virus (RSV) in infants and in calves has proven a challenging task. The design of recombinant antigens with a conformation close to their native form in virus particles is a major breakthrough. We compared two subunit vaccines, the bovine RSV (BRSV) pre-fusion F (preF) alone or with nanorings formed by the RSV nucleoprotein (preF+N). PreF and N proteins are potent antigenic targets for neutralizing antibodies and T cell responses, respectively. To tackle the challenges of neonatal immunization, three groups of six one-month-old calves with maternally derived serum antibodies (MDA) to BRSV received a single intramuscular injection of PreF, preF+N with Montanide™ ISA61 VG (ISA61) as adjuvant or only ISA61 (control). One month later, all calves were challenged with BRSV and monitored for virus replication in the upper respiratory tract and for clinical signs of disease over one week, and then post-mortem examinations of their lungs were performed. Both preF and preF+N vaccines afforded safe, clinical, and virological protection against BRSV, with little difference between the two subunit vaccines. Analysis of immune parameters pointed to neutralizing antibodies and antibodies to preF as being significant correlates of protection. Thus, a single shot vaccination with preF appears sufficient to reduce the burden of BRSV disease in calves with MDA.
Databáze: OpenAIRE
Externí odkaz: